Bal Pharma liquidity ratios

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

1.65×	—	—	—	—	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
1.05×	1.05×	1.07×	1.15×	1.09×
0.59×	0.59×	0.60×	0.72×	0.62×
4.4	4.4	4.2	11.0	1.5
13.0	13.0	15.4	31.1	18.8

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

BALPHARMA₹84.61

Bal Pharma Limited

· Pharma & Health

₹ CrorePeersALPA KREBSBIO NATCAPSUQ VINEETLAB NECLIFE AAREYDRUGS BIOFILCHEM MANGALAMMcap ₹135 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Altman Z-Score (Other Equity as RE)	—	—	—	—	1.65
Current Ratio	1.09	1.15	1.07	1.05	1.05
Quick Ratio	0.62	0.72	0.60	0.59	0.59
Cash, Equiv & ST Investments	1.5	11.0	4.2	4.4	4.4
Working Capital	18.8	31.1	15.4	13.0	13.0

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.